{
    "clinical_study": {
        "@rank": "144454", 
        "arm_group": [
            {
                "arm_group_label": "122-0551", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Corticosteroids are one of the mainstays of treatment for subjects with\n      corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to\n      determine and compare the efficacy and safety of a formulation of 122-0551 versus the\n      corresponding Vehicle in subjects with stable plaque psoriasis after twice daily dosing for\n      14 consecutive days."
        }, 
        "brief_title": "A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Psoriasis", 
            "Plaque Psoriasis"
        ], 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a clinical diagnosis of stable plaque psoriasis\n\n          -  Subject has an ODS score for the Treatment Area of 3 or 4 at study start\n\n        Exclusion Criteria:\n\n          -  Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.\n\n          -  Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.\n\n          -  Subject has used any phototherapy, photo-chemotherapy or systemic corticosteroid\n             therapy within 30 days prior to study start\n\n          -  Subject has used any systemic methotrexate, retinoids, cyclosporine or analogous\n             products within 90 days prior to study start\n\n          -  Subject has used any systemic biologic therapy for the treatment of psoriasis within\n             5 half-lives of the biologic prior to study start\n\n          -  Subject had prolonged exposure to natural or artificial sources of ultraviolet\n             radiation within 30 days prior to study start\n\n          -  Subject has used topical body (excluding the scalp) psoriasis therapy including coal\n             tar, anthralin, steroids, retinoids, vitamin D analogs (e.g., Dovonex\u00ae) within 14\n             days prior to study start\n\n          -  Subject has used emollients/moisturizers on areas to be treated within four hours\n             prior to clinical evaluation at study start\n\n          -  Subject is currently using lithium or Plaquenil (hydroxychloroquine)\n\n          -  Subject is currently using a beta-blocking medication (e.g., propanolol) or ACE\n             (e.g., lisinopril) inhibitor at a dose that has not been stabilized\n\n          -  Subject is pregnant, lactating, or is planning to become pregnant during the study\n\n          -  Subject is currently enrolled in an investigational drug or device study\n\n          -  Subject has used an investigational drug or investigational device treatment within\n             30 days prior to study start\n\n          -  Subject has been previously enrolled in this study and treated with a test article"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01700985", 
            "org_study_id": "122-0551-203"
        }, 
        "intervention": [
            {
                "arm_group_label": "122-0551", 
                "description": "Applied twice daily for two weeks", 
                "intervention_name": "122-0551", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "description": "Applied twice daily for two weeks", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "psoriasis", 
            "plaque psoriasis", 
            "122-0551", 
            "steroid"
        ], 
        "lastchanged_date": "November 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }, 
                    "name": "Therapeutics Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78759"
                    }, 
                    "name": "DermResearch, Inc."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment", 
        "overall_official": {
            "affiliation": "Therapeutics, Inc.", 
            "last_name": "Syd Dromgoole, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The proportion of subjects with ODS \"treatment success\" at EOS where EOS is the subject's last completed visit.  \"Treatment success\" is defined as an ODS of 0 or 1.  ODS is measured on a 5-point scale: 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe/very severe.", 
            "measure": "Change in Overall Disease Severity (ODS) Score", 
            "safety_issue": "No", 
            "time_frame": "baseline and Day 15 (End of Study - EOS)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01700985"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The proportion of subjects with ODS \"treatment success\" at Day 8 and Day 15.", 
                "measure": "ODS \"treatment success\" at Day 8 and Day 15", 
                "safety_issue": "No", 
                "time_frame": "baseline, Day 8, and Day 15"
            }, 
            {
                "description": "The proportion of subjects rated \"improved\" with respect to ODS at Days 8 and 15.  \"Improved\" is defined as at least a 2 grade decrease in ODS score relative to baseline.", 
                "measure": "ODS \"improved\" at Day 8 and Day 15", 
                "safety_issue": "No", 
                "time_frame": "baseline, Day 8, and Day 15"
            }, 
            {
                "description": "The proportion of subjects rated \"treatment success\" for each of the clinical signs and symptoms of psoriasis (scaling, erythema, plaque elevation) at Days 8 and 15.", 
                "measure": "\"Treatment success\" for clinical signs and symptoms of psoriasis", 
                "safety_issue": "No", 
                "time_frame": "baseline, Day 8 and Day 15"
            }, 
            {
                "description": "The proportion of subjects rated \"improved\" for each of the clinical signs and symptoms of psoriasis (scaling, erythema, plaque elevation, pruritus) at Days 8 and 15.", 
                "measure": "\"Improved\" for clinical signs and symptoms of psoriasis", 
                "safety_issue": "No", 
                "time_frame": "baseline, Day 8 and Day 15"
            }, 
            {
                "description": "Changes in % BSA with active psoriasis in the Treatment Area at Days 8 and 15.", 
                "measure": "Change in % body surface area (BSA) with psoriasis", 
                "safety_issue": "No", 
                "time_frame": "baseline, Day 8 and Day 15"
            }
        ], 
        "source": "Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}